Argenx

This program provides efgartigimod PH20 SC to adults with CIDP who cannot join a clinical trial and have not gotten better with standard treatments like steroids or immunoglobulins. The goal is to offer a potential treatment option for those with active disease and unmet medical …

This study tests if empasiprubart works as well as or better than standard IVIg treatment for adults with multifocal motor neuropathy (MMN), a rare nerve condition that causes muscle weakness. About 115 people who already respond to IVIg will be randomly assigned to get either em…

This study tests a new drug called efgartigimod for people who have kidney transplant rejection caused by antibodies. About 30 adults who had a kidney transplant at least 6 months ago and have active rejection will receive the drug or a placebo as a shot under the skin. They will…

This early-stage study tests a new medicine called ARGX-119 in 16 adults with a rare genetic condition (DOK7-CMS) that causes muscle weakness. The main goal is to check if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo, and la…

This study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over two years to see how well the drug works in real…

This study tests an investigational drug called efgartigimod in 81 adults with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. Participants receive either the drug or a placebo for up to 48 weeks. The main goal is to see if the drug reduc…

This study is testing different drug combinations to find safer and more effective treatments for people with myasthenia gravis, a condition that causes muscle weakness. About 70 adults with generalized MG will try either a new drug alone or added to their current treatment. The …

This study compares a new intravenous drug, empasiprubart, to standard intravenous immunoglobulin (IVIg) in 218 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. Participants first receive either empasiprubart or…

This study tests an investigational IV drug called efgartigimod in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. About 69 participants will receive either the drug or a placebo for up to 24 weeks…

This study tests a drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to find the right dose and check for side effects. Participants receive injections and are monitored for up to 14 weeks.

This study is testing a drug called efgartigimod in adults who have been diagnosed with generalized myasthenia gravis (gMG) within the past year. The goal is to see if the treatment can reduce muscle weakness and improve daily activities. Participants will receive the drug for 51…

This study tests a new drug called empasiprubart for adults with CIDP, a condition that causes nerve damage and weakness. About 160 people will receive either the drug or a placebo for 6 months, then everyone gets the drug for 2 more years. The goal is to see if it improves disab…

This study tests an investigational drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The trial aims to understand how the drug works in young bodies, its safety, and its effects. Up to 12 participants w…

This study tests an IV medicine called efgartigimod in teens aged 12 to 18 who have had immune thrombocytopenia (ITP) for over a year. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet levels.…

This study tests whether adding empasiprubart to the standard treatment efgartigimod can further improve symptoms in people with a specific type of generalized myasthenia gravis (gMG). About 70 adults who still have partial symptoms despite efgartigimod will receive the combinati…

This study tests a new medicine, ARGX-119, in children aged 5 to 17 with spinal muscular atrophy (SMA). The goal is to find the right dose and check if it is safe and helps improve movement. All children will continue their usual SMA treatments. The study lasts about 2 years, wit…

This study is for people aged 2 and older with certain rare types of congenital myasthenic syndrome (CMS) caused by specific gene changes. Researchers will collect information from up to 4 visits to track symptoms, medication use, and quality of life. The goal is to better unders…

This early-stage study tests the safety of a new drug called ARGX-124 in healthy adults. Researchers will also measure how the drug behaves in the body and how the immune system reacts. About 104 participants will be involved for up to 23 weeks. The goal is to gather important sa…

This study monitors the long-term safety of the drug efgartigimod in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. About 680 participants will be followed, some taking efgartigimod and others not, to compare risks like serious infection…

This study follows pregnant or breastfeeding women who have taken efgartigimod for myasthenia gravis or CIDP. Researchers will monitor mothers, fetuses, and infants for any health issues, including birth defects. The goal is to gather safety data, not to test a new treatment.